Miami, FL – July 16, 2024 – Cordis, a global leader in the development and manufacturing of interventional cardiovascular and endovascular technology, has been awarded a national group purchasing agreement for Vascular Closure Devices with Premier.  Effective July 9, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the MYNX CONTROL™ VENOUS Vascular Closure Device (VCD).

“We are thrilled to have been awarded a national agreement with Premier.  MYNX CONTROL™ VENOUS VCD is available for Premier members performing mid-bore venous procedures, including electrophysiology ablation procedures, to achieve consistent and effective extravascular closure, ultimately facilitating quick and safe patient ambulation.” said Matt Muscari, Cordis President, Americas.  “This agreement provides Premier members access to innovative technology with clinically proven reductions in time to hemostasis, time to ambulation, and time to discharge eligibility, supporting improved facility workflow.”

The MYNX CONTROL™ VENOUS VCD is an extravascular closure device designed to pair procedural simplicity with enhanced safety and reliability.  Leveraging GRIP TECHNOLOGY™, based on hydrophilic, bioinert polyethylene glycol (PEG), the MYNX CONTROL™ VENOUS VCD sealant resorbs 3x faster than collagen-based sealants and provides the quickest time to hemostasis of any venous closure device currently on the market.  

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services; Premier enables better care and outcomes at lower costs.

About Cordis

Cordis is a global leader in the development and manufacturing of interventional cardiovascular and endovascular technologies. For over 60 years, we have remained committed to improving patients’ lives through innovation, enhanced clinical outcomes, education, and service.  Our mission is to be the heart of innovation to transform cardiovascular care.
 

For more information about Cordis, please visit Cordis.com and follow Cordis on LinkedIn.